BridgeBio Pharma at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

BridgeBio Pharma at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
BridgeBio Pharma Greater Chicago Area	1 Statistical Geneticist
bridgebio.com\|LinkedIn Public company~556 people BridgeBio develops medicines for genetic conditions and underserved patient populations. Its portfolio spans ATTR-CM, LGMD2I/R9, ADH1, and skeletal dysplasias. Dosed the first patient in a new Phase 3b/4 study on the long-term effects of its heart-disease drug acoramidis. › Dosed the first patient in a new Phase 3b/4 study on the long-term effects of its heart-disease drug acoramidis. 2026-08 · source Priced a secondary share offering by shareholder KKR, diversifying its investor base without raising new company capital. 2026-08 · source Got FDA acceptance of its drug application for encaleret, treating a rare genetic calcium disorder called ADH1, moving it toward approval. 2026-07 · source Source: company newsroom Q2 2026 revenue $243.7M, up ~120% YoY › Growth driven mainly by $222.4 million in US net sales of its heart drug Attruby. · 2026-08-10 “The second quarter total revenues, net totaled $243.7 million, comprised of $222.4 million of U.S. Attruby net product revenue” Source: results release Currently hiring: 62 open roles › Source: careers page	Poster Thu Oct 22 4:15 pm Part of Genetic, Genomic, and Epigenomic Resources and Databases Poster Thursday Session Real-world genotypic landscape of PKU from the National PKU Alliance Patient Registry Exhibit & Poster Hall · Board 4046T DatabasesGenetic epidemiologyMetabolic disorderVariant interpretation

Organization

ASHG 2026 Attendance

BridgeBio Pharma

Greater Chicago Area

1 Statistical Geneticist

bridgebio.com|LinkedIn

Public company~556 people

BridgeBio develops medicines for genetic conditions and underserved patient populations. Its portfolio spans ATTR-CM, LGMD2I/R9, ADH1, and skeletal dysplasias.

Dosed the first patient in a new Phase 3b/4 study on the long-term effects of its heart-disease drug acoramidis.

›

Dosed the first patient in a new Phase 3b/4 study on the long-term effects of its heart-disease drug acoramidis.

2026-08 · source

Priced a secondary share offering by shareholder KKR, diversifying its investor base without raising new company capital.

2026-08 · source

Got FDA acceptance of its drug application for encaleret, treating a rare genetic calcium disorder called ADH1, moving it toward approval.

2026-07 · source

Source: company newsroom

Q2 2026 revenue $243.7M, up ~120% YoY

›

Growth driven mainly by $222.4 million in US net sales of its heart drug Attruby. · 2026-08-10

“The second quarter total revenues, net totaled $243.7 million, comprised of $222.4 million of U.S. Attruby net product revenue”

Source: results release

Currently hiring: 62 open roles

›

Source: careers page

Poster

Thu Oct 22
4:15 pm

Part of Genetic, Genomic, and Epigenomic Resources and Databases Poster Thursday Session

Real-world genotypic landscape of PKU from the National PKU Alliance Patient Registry

Exhibit & Poster Hall · Board 4046T

DatabasesGenetic epidemiologyMetabolic disorderVariant interpretation

Instantly find 20 buyers from BridgeBio Pharma

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction